- Browse by Subject
Browsing by Subject "CPIC"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy(Wiley, 2019-04-21) Desta, Zeruesenay; Gammal, Roseann S.; Gong, Li; Whirl-Carrillo, Michelle; Gaur, Aditya H.; Sukasem, Chonlaphat; Hockings, Jennifer; Myers, Alan; Swart, Marelize; Tyndale, Rachel F.; Masimirembwa, Collen; Iwuchukwu, Otito F.; Chirwa, Sanika; Lennox, Jeffrey; Gaedigk, Andrea; Klein, Teri E.; Haas, David W.; Medicine, School of MedicineThe human immunodeficiency virus (HIV) type-1 non-nucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by CYP2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.Item Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors(Wiley, 2015-08) Hicks, J. Kevin; Bishop, Jeffrey R.; Sangkuhl, Katrin; Müller, Daniel J; Ji, Yuan; Leckband, Susan G.; Leeder, J. Steven; Graham, Rebecca L.; Chiulli, Dana L.; LLerena, Adrián; Skaar, Todd C.; Scott, Stuart A.; Stingl, Julia C.; Klein, Teri E.; Caudle, Kelly E.; Gaedigk, Andrea; Department of Medicine, IU School of MedicineSelective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).Item Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen B (HLA-B) Genotype and Allopurinol Dosing: 2015 update(Wiley, 2016-01) Saito, Yoshiro; Stamp, Lisa K.; Caudle, Kelly E.; Hershfield, Michael; McDonagh, Ellen M.; Callaghan, John T.; Tassaneeyakul, Wichittra; Mushiroda, Taisei; Kamatani, Naoyuki; Goldspiel, Barry R.; Phillips, Elizabeth J.; Klein, Teri E.; Lee, Ming Ta Michael; Department of Pharmacology and Toxicology, IU School of MedicineThe Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).Item The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting(Wiley, 2017-05) Cavallari, LH; Beitelshees, AL; Blake, KV; Dressler, LG; Duarte, JD; Elsey, A; Eichmeyer, JN; Empey, PE; Franciosi, JP; Hicks, JK; Holmes, AM; Jeng, LJB; Lee, CR; Lima, JJ; Limdi, NA; Modlin, J; Obeng, AO; Petry, N; Pratt, VM.; Skaar, Todd C.; Tuteja, S; Voora, D; Wagner, M; Weitzel, KW; Wilke, RA; Peterson, JF; Johnson, JA; Health Policy and Management, School of Public HealthItem Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward(Future Medicine, 2018-07-01) Caudle, Kelly E.; Keeling, Nicholas J.; Klein, Teri E.; Whirl-Carrillo, Michelle; Pratt, Victoria M.; Hoffman, James M.; Medical & Molecular Genetics, IU School of MedicineSuccessfully implementing pharmacogenomics into routine clinical practice requires an efficient process to order genetic tests and report the results to clinicians and patients. Lack of standardized approaches and terminology in clinical laboratory processes, ordering of the test and reporting of test results all impede this workflow. Expert groups such as the Association for Molecular Pathology and the Clinical Pharmacogenetics Implementation Consortium have published recommendations for standardizing laboratory genetic testing, reporting and terminology. Other resources such as PharmGKB, ClinVar, ClinGen and PharmVar have established databases of nomenclature for pharmacogenetic alleles and variants. Opportunities remain to develop new standards and further disseminate existing standards which will accelerate the implementation of pharmacogenomics.